Status:
COMPLETED
Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 in Mild Alzheimer's Patients.
Lead Sponsor:
Novartis
Conditions:
Alzheimer Disease
Eligibility:
All Genders
40-85 years
Phase:
PHASE2
Brief Summary
This study will evaluate the safety and tolerability of repeated subcutaneous injections of CAD106 in patients with mild Alzheimer's disease.
Eligibility Criteria
Inclusion
- Diagnosis of Mild Alzheimer's Disease
- Mini-Mental State Examination (MMSE) 20 to 26 at screening, untreated or on stable dose of cholinesterase inhibitor or memantine over the last 6 weeks
Exclusion
- Previously participated in an AD vaccine study and received active treatment
- History or presence of an active autoimmune and/or with an acute or chronic inflammation, and/or clinically relevant atopic condition.
- History or presence of seizures and/or cerebrovascular disease.
- Presence of an other neurodegenerative disease and/or psychiatric disorders (with the exception of successfully treated depression)
Key Trial Info
Start Date :
July 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
27 Patients enrolled
Trial Details
Trial ID
NCT00733863
Start Date
July 1 2008
Last Update
February 11 2020
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Hospitalier Universitaire Pellegrin
Bordeaux, France
2
Karolinska Universitetssjukhuset Huddinge
Stockholm, Sweden
3
NeuroPsychologieZentrum
Basel, Switzerland
4
Moorgreen Hospital
Southampton, United Kingdom